Information from a new study is suggesting that the chronic inflammatory condition psoriasis is linked to an increased risk for patients developing atrial fibrillation (AF) and ischaemic stroke.
Researchers on the Danish study analyzed data collected from 36,765 participants who had mild psoriasis and 2,793 patients with severe psoriasis. Researchers then sought to compare those patients with patients that had been diagnosed with AF and had suffered an ischaemic stroke. The purpose of the study was to see if the psoriasis was directly linked to the risk of AF and stroke. The researchers chose to use multivariable Poisson’s regression and sensitivity analyses to conduct their research.
According to a published report on Medscape.com, the research found that psoriasis is a risk factor for these adverse cardiovascular events. The relative risks of AF and ischaemic stroke were highest in young patients with severe psoriasis. The results add to accumulating evidence, indicating that patients with psoriasis are at increased cardiovascular risk. Studies that more accurately account for important cardiovascular risk factors and immunomodulatory treatment are awaited to confirm this novel association and prospective randomized trials are needed.
Stroke risks are very serious in AF patients. Many different types of medications are used to treat AF while trying to prevent strokes. The most popular right now is Warfarin, but Apixaban and Dabigatran are quickly gaining ground. Multaq, made by Sanofi-Aventis used to be considered a viable treatment option for AF patients, but that has changed dramatically after it was discovered that the drug causes liver failure and a worsening of the heart condition for some patients.
If you or a loved one has suffered from liver failure or a worsening heart condition after being treated with Multaq, contact the attorneys at Greg Jones today for a free consultation. I am experienced at fighting Multaq lawsuits and may be able to help you recover money for your injuries.